IL-SILKROAD-TECHNOLOGY
28.5.2020 14:02:05 CEST | Business Wire | Press release
SilkRoad Technology, a global software and services platform that helps organisations attract, retain and align people to its business, today announced its recognition as a Core Leader in the 2020 Fosway 9-Grid™ for Talent Acquisition. This position acknowledges SilkRoad Technology for growth and innovation in its talent experience capabilities, as well as for the company's continued customer growth, success and advocacy across the European market.
SilkRoad Technology’s Talent Acquisition services and software help organisations optimise talent by attracting the right calibre of candidate to the business. HR and business decision-makers can streamline recruiting processes from requisition to job offer through SilkRoad’s scalable, personalised and on-brand solution that drives engagement and retention. Once the right talent is identified and secured, SilkRoad’s onboarding solution provides clarity, alignment and enablement to employees which helps accelerate revenue for efficient cost management in the midst of evolving workforce transformation.
“Being viewed as a Core Leader by Fosway is a great achievement for SilkRoad Technology. The Talent acquisition marketplace continues to face significant change and disruption particularly in these extremely difficult times. That’s why we continue to heavily invest finances and staff time in the development of our solution’s, so they are fit not only for today’s business challenges but also agile enough to evolve for the challenges of tomorrow as well,” said Colin Larter, Senior Director, SilkRoad EMEA.
The Fosway Group 9-Grid™ is a five-dimensional market analysis model that helps organisations understand the relative position of solutions and providers in the learning and talent systems market. It is based on Fosway Group’s independent research in the HR, talent and learning market throughout the past 20 years, and draws on insight and experience of its Corporate Research Network. The Corporate Research Network is a group of HR and learning professionals, who among them represent more than 150 of Europe’s leading companies. The 2018 Fosway 9-Grid™ for Talent Acquisition is available here .
“Silkroad is a new addition to the 2020 Fosway 9-Grid™ for Talent Acquisition. Whilst Silkroad plays in multiple parts of the talent lifecycle, its specialist focus on onboarding is central to our assessment and rating as a Core Leader,” said David Wilson, CEO of Fosway Group. “SilkRoad’s recognition reflects its proven capability to provide European companies with much needed expertise in a critical area of success.”
About Fosway
Fosway Group is Europe's #1 HR Industry Analyst. The Fosway 9-Grid provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The 9-Grids help European buyers demystify supplier decisions for next gen HR, Talent and Learning. Fosway Group have provided expert independent advice to corporate clients for over 20 years.
Visit the Fosway website at www.fosway.com for more information on Fosway Group's research and services.
About SilkRoad Technology
Since 2003, SilkRoad Technology’s software and services platform helps our clients attract, retain and align people to their business. Our solutions start with Global Client Services to provide strategic HR and business expertise. SilkRoad then designs secure solutions tailored to your business requirements at scale for global companies. We deliver personalised experiences for employees to drive engagement across the employment lifecycle to enable measurable and better business outcomes.
For more information, visit www.silkroadtechnology.com , follow on Twitter @SilkRoadTweets or call 866-329-336. (U.S. toll free) or +1-312-574-3700.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005286/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom